Hoyoung Huh, M.D., PH.D.

Hoyoung Huh, M.D., Ph.D., is the chairman of Geron Corporation, where he has also held executive chairman and director positions, and is on the board of directors for Addex Pharmaceuticals. Dr. Huh has been involved in the formation, management and financing of more than 20 successful entities across the United States, Europe and Asia. He was previously the president, chief executive officer and chairman of BiPar Sciences Inc., which was acquired by Sanofi-aventis in 2009. Prior to that, he served as the chairman of Epizyme Inc., chief operating officer and board member of Nektar Therapeutics and board member of Facet Biotech, which was acquired by Abbott Laboratories in 2010. Dr. Huh was formerly a partner at McKinsey & Company in the healthcare and technology practices. Dr. Huh holds a B.S. in biochemistry from Dartmouth College, an M.D. from Cornell University Medical College, and a Ph.D. in genetics and cell biology from Cornell University/Sloan-Kettering Institute.

Sean McCarthy, D. Phil.
President and Chief Executive Officer

Dr. McCarthy joined CytomX in 2010 and has more than twenty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the DNAX Research Institute (now part of Merck) Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium he joined SGX Pharmaceuticals where he spearheaded a wide range of large pharma partnerships as Vice President Business Development prior to the acquisition of the company by Lilly. Immediately before joining CytomX Dr. McCarthy was a transactional partner at venture capital firm Pappas Ventures responsible for investments in therapeutic, medical device and molecular diagnostic companies including Afferent Pharmaceuticals (acquired by Merck), TyRx (acquired by Medtronic), Lumena (acquired by Shire), CoLucid (acquired by Lilly) and LEAD Therapeutics, the originator of talazoparib, now a Phase 3 product candidate in the Pfizer pipeline. Dr. McCarthy is an author on multiple peer-reviewed scientific publications, issued patents and filed patent applications. He received his B.Sc. in biochemistry and pharmacology at King’s College, University of London; his M.B.A. from the Rady School of Management at UC San Diego; and a D. Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy is a Board member of the California Life Sciences Association.

Charles S. Fuchs, M.D., M.P.H.
Charles S. Fuchs, M.D., M.P.H., is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development, and conducts research assessing novel therapeutic approaches in oncology. Dr. Fuchs is the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the Yale Cancer Center and Physician-in-Chief of the Smilow Cancer Hospital. He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health.
Fred Gluck

Fred Gluck is a former managing partner (chief executive) of McKinsey & Company Inc. After retiring from McKinsey in 1995, he joined the Bechtel Group, where he served as vice chairman and director. He later rejoined McKinsey & Company as a consultant until retiring again in July 2003. Mr. Gluck was the founding chairman and CEO of both CytomX and Cynvenio Biosystems and continues to serve as chairman of Cynvenio. He also serves as director of a number of eleemosynary organizations, including the Foundation Board of the University of California, Santa Barbara, the Kavli Institute of Theoretical Physics and The New York Presbyterian Hospital (Emeritus). He recently retired from the Board of Amgen and was the presiding director of HCA (Hospital Corporation of America). Mr. Gluck received his B.S. from Manhattan College and an M.S. from New York University: both degrees in electrical engineering.

Marion McCourt
Marion McCourt has more than two decades of operational and commercial leadership experience at several of the world's most innovative biopharmaceutical companies. Ms. McCourt most recently served as Chief Operating Officer at Medivation until the company’s acquisition by Pfizer in September 2016. Prior to joining Medivation in February 2016, Ms. McCourt served as Vice President of U.S. Commercial Operations at Amgen Inc. Prior to that, she also served as Vice President and General Manager of Amgen's Bone Health & Primary Care Business Unit. Before joining Amgen, Ms. McCourt held numerous positions of increasing responsibility over a twelve-year career at AstraZeneca. There, she most recently served as Chief Operating Officer of AstraZeneca U.S., where she was responsible for all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations and corporate affairs. Ms. McCourt holds a B.S. degree in Biology from Lafayette College.
Matthew Young

Matthew P. Young was appointed executive vice president and chief financial officer of Jazz Pharmaceuticals in February 2015. He previously had served as senior vice president and chief financial officer of Jazz since March 2014 and as senior vice president, corporate development of Jazz since April 2013. Prior to joining Jazz, Mr. Young worked in investment banking for approximately 20 years. From February 2009 to April 2013, he served as a managing director in global healthcare of Barclays Capital Inc., an investment banking firm, where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., an investment banking firm, and from 2003 to 2007, as a managing director of Lehman Brothers Inc., an investment banking firm. In 2015, he joined the board of directors of PRA Health Sciences Inc., a contract research company. Mr. Young received a B.S. in economics and a M.B.A. from the Wharton School of the University of Pennsylvania.

John Scarlett, M.D.
John “Chip” A. Scarlett currently serves as chief executive officer, president and a member of the board of directors of Geron Corporation. Since February 2015, Dr. Scarlett has also served as a member of the board of directors of Chiasma, Inc. Prior to joining Geron in 2011, Dr. Scarlett served as president, chief executive officer and a member of the board of directors of Proteolix, Inc., from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., in November 2009. From February 2002 until its acquisition by Ipsen, S.A., in October 2008, Dr. Scarlett served as founder, chief executive officer and a member of the board of directors of Tercica, Inc., and also as its president from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as president and chief executive officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as senior vice president of medical and scientific affairs at Novo Nordisk Pharmaceuticals, Inc. Dr. Scarlett holds a B.A. in chemistry from Earlham College and an M.D. from the University of Chicago, Pritzker School of Medicine.